Absenteeism and health-benefit costs among employees with MS

Current Medical Research and Opinion

Volumn 25, Issue 6, 2009, Pages 1469-1476

  Brook, Richard A ^a,e   Rajagopalan, Krithika ^b   Kleinman, Nathan L ^c   Melkonian, Arthur K ^d  

^a JeSTARx Group   (United States)

^b BIOGEN   (United States)

^c HCMS Group   (United States)

^d Human Capital Management Services   (United States)

^e Retrospective Analysis   (United States)

Author keywords

Absenteeism; Costs of care healthcare expenditures; Healthcare outcomes; Multiple sclerosis; Outcomes measurement; Pharmacoeconomics; Reimbursement payment methods

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ABSENTEEISM; ADULT; ARTICLE; BILLING AND CLAIMS; CHARLSON COMORBIDITY SCORE; CHI SQUARE TEST; CLINICAL ASSESSMENT TOOL; DEMOGRAPHY; DISABILITY; EMPLOYEE; FEMALE; HEALTH CARE COST; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; MULTIPLE SCLEROSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; PRESCRIPTION; RETROSPECTIVE STUDY; STUDENT T TEST; WORKMAN COMPENSATION;

ABSENTEEISM; ADULT; EMPLOYMENT; FEMALE; HEALTH BENEFIT PLANS, EMPLOYEE; HEALTH CARE COSTS; HUMANS; INSURANCE BENEFITS; MALE; MULTIPLE SCLEROSIS; PRESCRIPTION DRUGS; RETROSPECTIVE STUDIES; SICK LEAVE; UNITED STATES;

EID: 67649422325     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902905468     Document Type: Article

References (35)

1. Joy JE, Johnston RB, eds. Multiple Sclerosis: Current Status and Strategies for the Future Committee on Multiple Sclerosis. Washington, DC: National Academy Press, 2004. Available in part at: http://books.nap.edu/ execsumm-pdf/10031.pdf. Accessed March 3, 2008
2. National MS Society. Just the Facts. Frequently asked questions about MS and the National MS Society. Available at http://www.nationalmssociety.org/ about-multiple-sclerosis/ FAQs-about-MS/index.aspx#top. Accessed March 10, 2008
3. Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology 2002;58:136-138 (Pubitemid 34041953)
4. Kantarci O, Wingerchuk D. Epidemiology and natural history of multiple sclerosis: new insights. Curr Opin Neurol 2006;19:248-254 (Pubitemid 43804678)
5. Vollmer T. The natural history of relapses in multiple sclerosis. J Neurol Sci 2007;256:S5-13 (Pubitemid 46560640)
6. Philips CJ. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment. CNS Drugs 2004;18:561-574 (Pubitemid 38951779)
7. Johnson KL, Fraser RT.Mitigating the impact of multiple sclerosis on employment. Phys Med Rehabil Clin N Am 2005;16:571-582 (Pubitemid 40704684)
8. Minden SL, Frankel D, Hadden L, et al. The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics. Mult Scler 2006;12:24-38 (Pubitemid 43169235)
9. Vogenberg FR, Holland JP, Liebeskind D. Employer benefit design considerations for the era of biotech drugs. J Occup Environ Med 2007;49:626-632 (Pubitemid 46918854)
10. Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis. A cross-sectional study in the United States. Neurology 2006;66:1696-1702
11. Whetten-Goldstein K, Sloan FA, Goldstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998;4:419-425 (Pubitemid 28515352)
12. Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm 2007;13:245-61. Comment in: J Manag Care Pharm 2007;13:287-289 (Pubitemid 46730893)
13. Brown MG, Murray TJ, Sketris IS, et al. Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates. Int J Technol Assess Health Care 2000;16:751-767 (Pubitemid 30727635)
14. Iskedjian M, Walker JH, Gray T, et al. Economic evaluation of Avonex (interferon beta-1a) in patients following a single demyelinating event. Mult Scler 2005;11:542-551 (Pubitemid 41387699)
15. Nuijten MJ, Hutton J. Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Value Health 2002;5:44-54 (Pubitemid 34160370)
16. Prescott JD, Factor S, Pill M, et al. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007;13:44-52
17. Lage MJ, Castelli-Haley J, Oleen-Burkley MA. Effect of immunomodulatory therapy and other factors on employment loss time in multiple sclerosis. Work 2006;27:143-151 (Pubitemid 44355728)
18. The Health Insurance Portability and Accountability Act (HIPAA) Fact Sheet. U.S. Department of Labor, Employee Benefits Security Administration, December 2004 http:// www.dol.gov/ebsa/newsroom/fshipaa.html. Accessed 2-29-108
19. Kleinman NL, Brook RA, Rajagopalan K, et al. Lost time, absence costs, and reduced productivity output for employees with bipolar disorder. J Occup Environ Med 2005;47:1117-1124 (Pubitemid 41642502)
20. Brook RA, Kleinman NL, Patel PA, et al. The economic burden of gout in an employed population. Curr Med Res Opin 2006;22:1381-1389 (Pubitemid 44085590)
21. Gardner HH, Kleinman NL, Brook RA, et al. The impact of bipolar disorder on an employed population. J Clin Psychiatry 2006;67:1209-1218
22. Kleinman NL, Brook RA, Patel PA, et al. The impact of gout on work absence and productivity. Value Health 2007;10:231-237 (Pubitemid 47077244)
23. Brook RA, Kleinman NL, Rajagopalan K. Employee costs before and after treatment initiation for bipolar disorder. Am J Manag Care 2007;13:179-186 (Pubitemid 46608581)
24. Brook RA, Wahlqvist P, Kleinman NL, et al. Cost of gastrooesophageal reflux disease to the employer: a perspective from the United States. Aliment Pharmacol Ther 2007;26:889-898 (Pubitemid 47346705)
25. Wahlqvist P, Brook RA, Campbell SM, et al. Objective measurement of work absence and on-the-job productivity: a case-control study of US employees with and without gastroesophageal reflux disease. J Occup Environ Med 2008;50:25-31
26. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383 (Pubitemid 17055592)
27. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389-97. Comment in: Lancet 2007;370:363-4. Lancet 2007;370:2000; author reply 2000-2001 (Pubitemid 47189673)
28. Schwartz CE, Coulthard-Morris L, Cole B, et al. The quality of life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis. Arch Neurol 1997;54:1475-1480
29. Flacheneker P, Rieckmann P. Health outcomes in multiple sclerosis. Curr Opin Neurol 2004;17:257-261 (Pubitemid 38720976)
30. Gardner HH, Butler RJ, Gardner BD. Disability benefits when workers matter. Mind/Body Medicine 1997;2:138-149
31. Butler RJ. The economics of social insurance and employee benefits. Norwell, MA: Kluwer Academic Publishers, 1999
32. Beam BT, McFadden JJ. Employee Benefits, 5th edn. Chicago, IL: Dearborn Financial Publishing, Inc., 1998
33. Mathis RL, Jackson JH. Human Resource Management, 9th edn. Cincinnati, OH: South-Western College Publishing, 2000
34. Kleinman NL, Rajagopalan K, Brook RA, et al. Severity of illness among persons with multiple sclerosis: an analysis of cost quintiles. Value Health 2008;11:141-142
35. Roessler RT, Rumrill Jr PD, Hennessey ML, et al. Perceived strengths and weaknesses in employment policies and services among people with multiple sclerosis: results of a national survey. Work 2003;21:25-36 (Pubitemid 37038329)